NewAmsterdam Pharma Company NAMS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from NewAmsterdam Pharma Company’s reported figures.
Based on trailing twelve months.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's return on equity?
- NewAmsterdam Pharma Company (NAMS) reported return on equity of -29.5% in Q1 2026.
- How has NewAmsterdam Pharma Company's return on equity changed year-over-year?
- NewAmsterdam Pharma Company's return on equity increased by 6.4% year-over-year, from -31.5% to -29.5%.
- What is the long-term trend for NewAmsterdam Pharma Company's return on equity?
- Over 2 years (2023 to 2025), NewAmsterdam Pharma Company's return on equity has grown at a -24.2% compound annual growth rate (CAGR), from -49.3% to -28.3%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.